ETH Zürich is seeking two postdoctoral scientists to join the Institute for Chemical and Bioengineering, working under Dr Daniel A. Richards and Professor Andrew J. deMello. The positions focus on developing a novel diagnostic device for multidrug resistant Mycobacterium tuberculosis (MDR-MTB), aiming to create a simple, portable, and affordable point-of-care solution. This project is part of a multi-institutional consortium funded by the SNSF BRIDGE Discovery grant, involving partners such as the Swiss Centre for Microelectronics (CSEM), Swiss Tropical Public Health Institute (Swiss TPH), and the National Centre for Tuberculosis and Lung Disease (NCTLD) in Georgia. The research addresses the urgent global health challenge posed by tuberculosis, which remains the deadliest infectious disease worldwide, especially in low- and middle-income countries. The project seeks to overcome limitations of current diagnostic technologies by developing a paper-based, electrochemical platform capable of multiplexing 14 targets for TB and drug resistance markers from a single sample. The device leverages ETH Zürich's patented laser-induced graphenization of cellulose for affordable, scalable manufacturing, and integrates CRISPR–Cas-based biosensing assays for precise detection of single-nucleotide polymorphisms associated with drug resistance. Postdoctoral researchers will contribute to two main areas: (1) developing nucleic acid amplification tests and CRISPR–Cas assays, solid-phase electrochemical reporters, and evaluating assays with patient samples; (2) designing and fabricating miniaturized graphene-based electrodes, microfluidic devices, and software for fluidics handling and data analysis. Both roles involve close collaboration with academic and industrial partners, project management, presenting at conferences, and publishing research findings. Applicants should have a PhD in a relevant science or engineering discipline, with strong coding skills and experience in bioengineering, molecular biology, electrochemistry, device development, or computer science. The positions offer a multicultural, multidisciplinary research environment, access to state-of-the-art equipment, and strong career progression support. ETH Zürich values diversity, sustainability, and provides an inclusive culture for staff and students. Applications must be submitted online via the ETH Zürich portal, including a cover letter, detailed CV with publication list, and contact details for at least two references. Applications are reviewed continually, with interviews held online after shortlisting. The anticipated start date is in 2026. For further information, candidates may contact Dr Daniel Richards at [email protected] (no applications via email).

PhD Student in In Vitro Diagnostics: CRISPR–Cas and Electrochemical Biosensors for Tuberculosis Drug Resistance ETH Zürich, in collaboration with the Swiss Center for Electronics and Microtechnology (CSEM), the Swiss Tropical Public Health Institute, and the National Centre for Tuberculosis and Lung Disease in Georgia, invites applications for a fully funded PhD position. The project, led by Dr Daniel A. Richards, Professor Andrew J. deMello, and Dr Loïc Burr, focuses on developing advanced CRISPR–Cas-based electrochemical biosensors for the rapid and multiplexed detection of multidrug resistant Mycobacterium tuberculosis (MDR-MTB). Project Overview: Tuberculosis (TB) remains the deadliest infectious disease globally, with drug resistance posing a significant challenge, especially in low- and middle-income countries. This project aims to address the diagnostic gap by creating RPA–CRISPR–Cas assays capable of detecting TB and drug resistance markers from a single sample. The assays will be integrated with novel electrochemical reporters, enabling miniaturization and quantitative point-of-care diagnostics. The technology will be validated in patient samples and field-tested, offering the student opportunities for international collaboration and fieldwork. Research Environment: The successful candidate will join a multidisciplinary, multicultural team at ETH Zürich and CSEM, benefiting from state-of-the-art facilities, strong career support, and a vibrant academic community. The project is part of a SNSF BRIDGE Discovery grant and involves close collaboration with leading academic and industrial partners. Key Responsibilities: Develop nucleic acid amplification tests (NAATs) and CRISPR–Cas assays for MTB and MDR–MTB Design and implement solid-phase electrochemical reporters Evaluate assays using patient-derived samples Engage in protein expression and assay optimization Collaborate with international partners and contribute to project management Present research at conferences and publish in peer-reviewed journals Eligibility: Applicants should hold a Master’s degree in a relevant science or engineering field (e.g., bioengineering, molecular biology, chemistry, analytical chemistry). Experience with CRISPR–Cas, biosensing, or electrochemistry is highly desirable. Candidates must demonstrate motivation, strong communication skills, and the ability to work in a collaborative, international environment. Proficiency in English is required. Funding: The position is fully funded for four years through a SNSF BRIDGE Discovery grant, offering attractive hiring conditions and comprehensive research support. Application Process: Applications are accepted exclusively via the ETH Zürich online portal. Required documents include a cover letter, detailed CV, and contact information for at least two references. Applications are reviewed on a rolling basis, with interviews scheduled after shortlisting. The anticipated start date is in 2026. For further information, contact Dr Daniel Richards ([email protected]) or Dr Loïc Burr ([email protected]). For more details about the deMello group and CSEM, visit their respective websites. ETH Zürich is committed to diversity, inclusion, and sustainability, providing an environment where all staff and students can thrive.